Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

IGC Pharma, Inc.

35 indications, side-by-side phase, drug & LoA

$0.28

0 (-0.88%)

D 27Pipeline Score Richly Valued Biotech · Clinical
Market Cap
28.83 M
EPS
-
P/E Ratio
-
Value Trade
480.87 K
SEC Financials
Q1 2026

  • Dilution Risk

    95%

  • Revenue

    317.00 K

  • R&D Expenses

    1.27 M

  • Operating CF

    -1.22 M

  • Total Assets

    9.19 M

  • Total Liabilities

    3.06 M

  • Equity

    6.12 M

  • D/E Ratio

    12,345

-2.07 %
Week
-8.16 %
1 Month
14.74 %
3 Month
-8.16 %
6 Month
-79.43 %
5 Year
-99.47 %
All Time
Cash Data
Critical

  • Cash Position

    235.00 K

  • Monthly Burn

    408.00 K

  • Runway

    0 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
565.02 K
52 Week Range
0.24 - 0.50
% held by Insiders
23.1 %
% held by Institutions
4.25 %
Enterprise Value
29.52 M
Total Shares
98.84 M
Short %
1.6 %
Float Shares
73.53 M
Company Description
HQ: 10224 FALLS ROAD, POTOMAC, MD,...
Employees:70
https://www.igcinc.us

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 updated data readout example
IGC-AD1 Agitation in Alzheimer's dementia (symptomatic treatment); planned disease‑modifying investigations
Phase 2
—
-
-
IGC-AD1 Agitation in Alzheimer's dementia (symptomatic treatment); planned disease‑modifying investigations
Phase 2
—
-
-
IGC-AD1 Agitation in Alzheimer's dementia (symptomatic treatment); planned disease‑modifying investigations
Phase 2
—
-
-
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D27
Pipeline Score
$2M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Top 27%
Micro Cap
(rank 662 of 905)
Percentile Rank
IGC Pharma, Inc. faces pipeline headwinds (27/100), with $325M risk-adjusted pipeline value, led by IGC-AD1-Active in Alzheimer Disease (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IGC-AD1-Active
Small molecule		Alzheimer DiseasePhase 2NCT0554368111% $193M RECRUITING 164 AVERAGE B (66) Aug 1, 2026MODERATE_RISKMEDIUM
May 26, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
IGC-M3
Alzheimer's disease
Preclinical
2025-08-06
IGC-M3
Alzheimer's disease
Preclinical
2025-08-06
IGC-M3
Alzheimer's disease
Preclinical
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IGC
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IGC
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IGC Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IGC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest IGC Pharma, Inc. (IGC) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IGC ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Alzheimer's Disease #14 of 24 PHASE 2 IGC-AD1-Active
BMY LLY BIIB
$6.49B 0.85 FOLLOWER